시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 하이드록시클로로퀸 시장 보고서(2024년)
Hydroxychloroquine Global Market Report 2024
상품코드 : 1426208
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,234,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,851,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,469,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

하이드록시클로로퀸 시장 규모는 향후 몇 년 동안 크게 성장할 것으로 예상됩니다. 2028년에는 6.6%의 연평균 복합 성장률(CAGR)로 28억 6,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 복합 요법에 대한 수요 증가, 정부 자금 지원 노력 강화, 이러한 치료가 필요한 환자 수 증가, 의료 서비스 접근성 개선, 환자 맞춤형 의료에 대한 수요 증가 등 다양한 요인으로 인해 발생할 것으로 예상됩니다.

COVID-19 감염자 수가 급증하면서 하이드록시클로로퀸 시장 수요가 눈에 띄게 증가했으며, COVID-19 치료 및 진행 중인 임상시험에 대한 사용 증가가 이 수요를 촉진하고, COVID-19 입원 환자 및 임상시험에 등록된 환자들에 대한 긴급 사용이 미국 식품의약국(FDA)의 승인을 받음에 따라 미국 식품의약국(FDA)의 승인은 이러한 수요를 더욱 자극했습니다. 2023년 9월 21일 WHO 대시보드에 따르면, 전 세계 COVID-19 통계에 따르면 감염자 수는 7억 7,000만 명을 넘어섰고, 사망자 수는 약 700만 명에 달합니다. 미국, 브라질, 러시아, 영국, 인도, 스페인 등 국가가 가장 심각한 영향을 받았습니다. 그 결과, 전 세계 COVID-19 감염자 수가 지속적으로 증가함에 따라 하이드록시클로로퀸에 대한 수요가 증가하여 이 시장 부문의 수익이 증가하고 있습니다.

류마티스 관절염 환자가 증가할 것으로 예상되며, 이는 하이드록시클로로퀸 시장의 성장을 촉진할 것으로 예상됩니다. 류마티스 관절염은 신체 부위에 염증을 유발하는 자가면역 질환으로, 항염증 특성으로 인해 하이드록시클로로퀸의 효능을 누릴 수 있습니다. 미국에서는 약 5,440만 명의 성인이 관절염 진단을 받았으며, 2023년 6월 CDC의 예측에 따르면 2040년까지 7,800만 명에 달할 것으로 예상되어 류마티스 관절염의 유병률 증가는 하이드록시클로로퀸 시장을 견인할 것으로 보입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역 및 국가 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

제31장 경쟁 벤치마킹

제32장 경쟁 대시보드

제33장 주요 인수합병

제34장 향후 전망과 가능성 분석

제35장 부록

ksm
영문 목차

영문목차

Hydroxychloroquine, derived from the quinolone class of medications, is primarily used to treat malaria. In regions where other medications like chloroquine might not be effective, it's also employed to prevent malaria infection. Additionally, in some hospitalized individuals, hydroxychloroquine has been explored as a potential treatment for COVID-19 (COVID-19).

The key therapeutic activities associated with hydroxychloroquine include its use as an anti-malarial, anti-rheumatic, lupus suppressant, and potentially as an anti-COVID-19 agent. Antimalarial drugs, commonly known as 'antimalarials,' are chemical agents that combat parasites causing malaria. These drugs are often derived from natural sources. Hydroxychloroquine is available in various formulations such as tablets and injections, utilized in treating malaria, rheumatoid arthritis, lupus erythematosus, COVID-19, and other conditions. Its distribution spans across multiple channels including hospital pharmacies, online pharmacies, specialty drug stores, and retail pharmacies.

The hydroxychloroquine market research report is one of a series of new reports from The Business Research Company that provides hydroxychloroquine market statistics, including hydroxychloroquine industry global market size, regional shares, competitors with a hydroxychloroquine market share, detailed hydroxychloroquine market segments, market trends and opportunities, and any further data you may need to thrive in the hydroxychloroquine industry. This hydroxychloroquine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hydroxychloroquine market size has grown strongly in recent years. It will grow from $2.07 billion in 2023 to $2.22 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of malaria in certain regions, heightened awareness and utilization of hydroxychloroquine for malaria treatment and prevention, its wide availability in healthcare settings, and its application in managing autoimmune diseases. These elements collectively contributed to the increased usage and prominence of hydroxychloroquine during that time.

The hydroxychloroquine market size is expected to see strongly grown in the next few years. It will grow to $2.86 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. Anticipated growth in the forecast period is expected to stem from various factors, including the escalating demand for combination therapies, augmented government funding initiatives, a rising patient population requiring such treatments, improved access to healthcare services, and an increasing demand for personalized medicine tailored to individual needs.

The surge in COVID-19 cases has notably bolstered the demand for the hydroxychloroquine market. Its increasing usage in COVID-19 treatment and ongoing clinical trials has driven this demand. Authorization from the US FDA for emergency use in hospitalized COVID-19 patients and those enrolled in trials has further stimulated this demand. Global COVID-19 figures, as per the WHO Dashboard on September 21, 2023, indicate over 770 million confirmed cases and nearly 7 million deaths. Countries like the USA, Brazil, Russia, UK, India, and Spain have experienced the most significant impact. Consequently, the persistent rise in global COVID-19 cases is fueling demand for hydroxychloroquine, leading to heightened revenues in this market segment.

The projected escalation of rheumatoid arthritis cases is anticipated to drive growth in the hydroxychloroquine market. Rheumatoid arthritis, an autoimmune condition causing inflammation in affected body areas, benefits from hydroxychloroquine due to its anti-inflammatory properties. With approximately 54.4 million adults diagnosed with arthritis in the US, expected to reach 78 million by 2040 according to CDC projections in June 2023, the increased prevalence of rheumatoid arthritis is poised to propel the hydroxychloroquine market forward.

Noteworthy investments by key market players are aimed at expanding hydroxychloroquine production to meet rising demand and broaden product offerings. Aspen Pharmaceutical Corporation, in March 2021, received substantial funding of $20 billion from BNDES to bolster its hydroxychloroquine manufacturing in Brazil, part of a larger $153 million investment. This initiative, prompted by increased COVID-19-related demand, was lauded by the Brazilian government for ensuring an ample drug supply to meet population needs.

Strategic endeavors by major market entities involve expanding production capacities to address the amplified global demand for hydroxychloroquine. Ipca Laboratories Limited, in May 2021, reported hydroxychloroquine formulation sales of $4.44 million in the domestic market for a quarter. Projections for 2022 indicated an approximate $36.03 million capex for hydroxychloroquine formulation and associated projects, highlighting a significant push towards enhancing production capacities, especially at sites like Ratlam and others. This trend underscores the substantial efforts of key players shaping the hydroxychloroquine market landscape.In July 2021, Sanofi S.A, a France-based pharmaceutical and healthcare company and Asahi Kasei Pharma Corporation, a Japan-based specialty pharmaceutical firm have executed a marketing license agreement to transfer sales rights in Japan for Plaquenil tablets 200 mg, an immunomodulator. The agreement is aimed at expanding the availability of Plaquenil in Japan and improving patient access to the drug. Plaquenil is used to treat autoimmune diseases such as rheumatoid arthritis and lupus, and it has also been used in the treatment of COVID-19.

Major companies operating in the hydroxychloroquine market include Bayer AG, Dr. Reddy's Laboratories Ltd., Zydus Group, Ipca Laboratories Ltd., Wallace Pharma, Teva Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis AG, Intas Pharmaceuticals Ltd., Lupin Limited, Shanghai Zhongxi Sanwei Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., BSE healthcare, Hikma Pharmaceuticals PLC, Sandoz International GmbH, Cipla Limited, Shenhua Pharmaceutical Co. Ltd., Sanofi S.A., Macleod Pharmaceuticals Ltd., McW Healthcare, Laurus Labs, TAJ Pharmaceuticals, Wuhan Wuyao Pharmaceutical Co. Ltd., MAAN Medex, Cinkate Corporation, Concordia Healthcare, Pfizer Inc., Cadila Pharmaceuticals, Hetero Drugs Ltd., Jubilant Generics Limited, Alembic Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA Inc., Alkem Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Unichem Laboratories Ltd., Wockhardt Limited, Emcure Pharmaceuticals Ltd., Strides Pharma Science Ltd., Indoco Remedies Ltd.

North America was the largest region in the hydroxychloroquine market in 2023. Middle East is expected to be the fastest-growing region in the hydroxychloroquine market report. The regions covered in the hydroxychloroquine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the hydroxychloroquine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The hydroxychloroquine market consists of sales of plaquenil, antimalarials, and immunosuppressants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hydroxychloroquine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hydroxychloroquine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hydroxychloroquine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hydroxychloroquine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Scope

Markets Covered:

Table of Contents

1. Executive Summary

2. Hydroxychloroquine Market Characteristics

3. Hydroxychloroquine Market Trends And Strategies

4. Hydroxychloroquine Market - Macro Economic Scenario

5. Global Hydroxychloroquine Market Size and Growth

6. Hydroxychloroquine Market Segmentation

7. Hydroxychloroquine Market Regional And Country Analysis

8. Asia-Pacific Hydroxychloroquine Market

9. China Hydroxychloroquine Market

10. India Hydroxychloroquine Market

11. Japan Hydroxychloroquine Market

12. Australia Hydroxychloroquine Market

13. Indonesia Hydroxychloroquine Market

14. South Korea Hydroxychloroquine Market

15. Western Europe Hydroxychloroquine Market

16. UK Hydroxychloroquine Market

17. Germany Hydroxychloroquine Market

18. France Hydroxychloroquine Market

19. Italy Hydroxychloroquine Market

20. Spain Hydroxychloroquine Market

21. Eastern Europe Hydroxychloroquine Market

22. Russia Hydroxychloroquine Market

23. North America Hydroxychloroquine Market

24. USA Hydroxychloroquine Market

25. Canada Hydroxychloroquine Market

26. South America Hydroxychloroquine Market

27. Brazil Hydroxychloroquine Market

28. Middle East Hydroxychloroquine Market

29. Africa Hydroxychloroquine Market

30. Hydroxychloroquine Market Competitive Landscape And Company Profiles

31. Global Hydroxychloroquine Market Competitive Benchmarking

32. Global Hydroxychloroquine Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Hydroxychloroquine Market

34. Hydroxychloroquine Market Future Outlook and Potential Analysis

35. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기